Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV-AST Cell Injection
- Development stage
- Phase 2
- Lead developer
- Chinese PLA General Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
EBV-AST Cell Injection is an investigational adoptive cellular immunotherapy being developed by Daihong Liu at the Chinese PLA General Hospital. The therapy consists of Epstein-Barr virus (EBV) antigen-specific cytotoxic T lymphocytes generated by ex vivo stimulation and expansion of T cells using peptide-loaded dendritic cells. It is designed to treat EBV-associated lymphoproliferative disorders, including post-transplant lymphoproliferative disease (PTLD) and EBV-positive lymphomas, by restoring immune control over EBV-infected malignant cells. The product can be derived from either autologous or donor T cells and is administered via intravenous infusion to target EBV-infected cells expressing viral antigens.
- Other names
- Epstein-Barr virus antigen-specific T cellsEBV-specific cytotoxic T lymphocytesEBV-AST cell injection
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on EBV-AST Cell Injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV-AST Cell Injection.